Evidence map›Paper›PMID 40813111›Full record

ArticleJournal for immunotherapy of cancer2025

Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.

Zoe Quandt, Arabella Young, Graham Larson Barlow, Jennifer A Smith, Irina Kusmartseva, Shen Dong, Melanie R Shapiro, Jee Hye Kang, Jamie L Felton, Vinh Q Nguyen and 10 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zoe Quandt *Department of Medicine, University of California San Francisco, San Francisco, California, USA Zoe.Quandt@ucsf.edu.ORCID http://orcid.org/0000-0002-4568-4368
Arabella Young *Diabetes Center, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-6845-9753
Graham Larson BarlowDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Jennifer A SmithDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Irina KusmartsevaDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA.
Shen DongDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Melanie R ShapiroDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA.
Jee Hye KangDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Jamie L FeltonDepartment of Pediatrics, Division of Pediatric Endocrinology and the Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Vinh Q NguyenDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Greg SzotDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Assad A HassounDepartment of Surgery, California Pacific Medical Center, San Francisco, California, USA.
Ana Luisa PerdigotoDepartment of Internal Medicine, Yale University, New Haven, Connecticut, USA.
Kevan C HeroldDepartment of Internal Medicine, Yale University, New Haven, Connecticut, USA.
Garry NolanDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Paul L BollykyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Todd M BruskoDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA.
Maki NakayamaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Stewart CooperLiver Center, University of California San Francisco, San Francisco, California, USA.
Mark S AndersonDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0M
Engineered Immune Cells for T1DR01DK132549 · NIDDK · STANFORD UNIVERSITY · PI MEYER, EVERETT · 2022 to 2025
$3.1M
A stem cell activated cryogel bioscaffold that restores islet bioenergetics while providing oxygen and nutrients at extravascular sites of transplantationR01DK129343 · NIDDK · STANFORD UNIVERSITY · PI Avnesh Sinh Thakor · 2022 to 2026
$2.8M
The Stanford Clinical Center for the Study of Type 1 Diabetes in Acute PancreatitisU01DK127395 · NIDDK · STANFORD UNIVERSITY · PI Marina Basina, Walter Gwang-Up Park · 2020 to 2026
$2.2M
The Role of Hyaluronan and CD44 in the Pathogenesis of Type 2 DiabetesR01DK116782 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2020 to 2023
$1.6M
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunityR00CA246061 · NCI · UNIVERSITY OF UTAH · PI YOUNG, ARABELLA · 2022 to 2024
$747k
BD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573k
Fcγ Receptor-Mediated Pharmacogenomics of Antibody Therapies in Type 1 DiabetesK99DK140511 · NIDDK · UNIVERSITY OF FLORIDA · PI SHAPIRO, MELANIE R · 2024 to 2025
$265k
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunityK99CA246061 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOUNG, ARABELLA · 2020 to 2021
$251k
NCI NIH HHS K99 CA246061NCI NIH HHS R00 CA246061NIAID NIH HHS P01 AI042288NIDDK NIH HHS K12 DK133995NIDDK NIH HHS K99 DK140511NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK063720NIDDK NIH HHS R01 DK116782NIDDK NIH HHS R01 DK129343NIDDK NIH HHS R01 DK132549NIDDK NIH HHS U01 DK127395NIH HHS S10 OD021822
6 · The paper itself

Abstract

Immune checkpoint inhibitor-diabetes (CPI-D) is an acute and non-resolving immune-related adverse event (irAE) initiated primarily by disrupting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with monoclonal antibodies. A major limitation in understanding CPI-D is the lack of access to pancreatic tissue from patients experiencing this complication. We report a unique patient with no prior history of diabetes or autoimmune disease whose treatment with CPI for metastatic melanoma was complicated by CPI-D requiring insulin therapy. The patient then went on to develop pancreatic cancer. In the setting of the pancreatic cancer treatment, we were able to perform detailed single-cell RNA sequencing and immunophenotyping within the surgically resected pancreas. This revealed substantial lymphocytic infiltration associated with the islets, suggestive of an autoimmune rather than autoinflammatory mechanistic origin for CPI-D.

Indexed as

Diabetes MellitusImmune Checkpoint InhibitorsMelanomaPancreasPancreatic NeoplasmsAutoimmune DiseasesFemaleHumansImmunophenotypingMaleMiddle AgedImmune Checkpoint InhibitorsDiabetesImmune Checkpoint InhibitorImmune related adverse event - irAE

Identifiers

PMID40813111
PMCPMC12359507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.